AMS Planning, Inc.

Based in Japan, AMS Planning, Inc. specializes in developing and commercializing innovative nuclear medicine technologies, significantly impacting healthcare solutions for oncology and radiotherapy. Founded in 2019, AMS Planning, Inc. is involved in the advancement of nuclear medicine technologies.

The company is headquartered in Tokyo, Japan. In June 2025, AMS raised JPY 190 million in a pre-Series A funding round led by Miraisozo Investments and Vision Incubate, totaling JPY 190 million raised to date. The founder's prior entrepreneurial experience is not available. AMS Planning, Inc.

specializes in the development and commercialization of innovative nuclear medicine technologies aimed at transforming Japan's healthcare landscape. The company operates two primary business divisions: Theranostics Development (TD) and Engineering Solutions (ES). Within the TD division, AMS introduces next-generation Positron Emission Tomography (PET) diagnostics, notably including 68Ga-PSMA, and supports the development of novel radiotherapeutics such as astatine-211 (211At). These products address critical gaps in targeted oncology solutions designed to enhance the efficiency and effectiveness of cancer treatment.

The ES division focuses on the safe and efficient management of radioactive discharge through a proprietary bedside filtration system that improves regulatory compliance and patient throughput. AMS targets hospitals and healthcare providers across Japan, emphasizing scalable and impactful solutions for a healthcare system in need of modernization and increased operational capacity. AMS Planning, Inc. generates revenue through a combination of direct sales and strategic partnerships within the healthcare sector.

Transactions typically occur through B2B arrangements, with hospitals and medical institutions purchasing AMS's advanced diagnostic tools and therapeutic products to enhance their nuclear medicine capabilities. The pricing structure reflects the complexity and specialized nature of the products, with revenue streams arising from both the sale of radiopharmaceuticals and the implementation of the proprietary bedside filtration system. By streamlining operations and improving patient care, AMS drives revenue growth and positions itself as a vital partner for healthcare providers in Japan's evolving nuclear medicine market. The company’s flagship offerings, integral to its revenue model, underscore its commitment to addressing the increasing demand for innovative and efficient healthcare solutions.

AMS Planning, Inc. plans to utilize JPY 190 million raised in June 2025 to develop radiopharmaceutical businesses, support introductions to medical institutions in Japan and overseas, and recruit engineers, regulatory affairs, and business development personnel. Upcoming products include advanced therapeutic solutions set to launch by the end of 2025. The company aims to expand into international markets, particularly targeting regions in Southeast Asia, with a strategic rollout expected to commence in early 2026.